Zydus Lifesciences Adjusts Evaluation Amid Strong Financial Performance and Market Resilience
Zydus Lifesciences has recently experienced a change in its evaluation, reflecting a shift in market sentiment. The company showcases strong financial metrics, including a 10.59% annual growth in net sales and a low debt-to-equity ratio of 0.06, indicating solid financial health despite recent stock performance challenges.
Zydus Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape surrounding the stock, indicating a transition from a bullish to a mildly bullish trend. The company's performance metrics reveal a robust financial foundation, with net sales growing at an annual rate of 10.59% and operating profit increasing at 22.64%. Zydus Lifesciences maintains a low debt-to-equity ratio of 0.06 times, showcasing its strong financial health. Additionally, the company has consistently generated a return on equity averaging 19.49%, highlighting its efficiency in utilizing shareholder funds.
Despite a challenging year, where the stock returned -17.55%, Zydus Lifesciences has demonstrated resilience with a profit increase of 13.5%. The stock is currently trading at a fair value relative to its peers, supported by a price-to-book ratio of 4.1.
Overall, Zydus Lifesciences remains a significant entity within the market, ranked among the top 1% of companies evaluated by MarketsMojo.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
